Teva Pharma Trims FY22 Revenue Outlook - Update

While reporting financial results for the first quarter on Tuesday, Teva Pharmaceutical Industries Ltd (TEVA) trimmed its revenue guidance for the full-year 2022 to reflect ongoing impact of foreign exchange fluctuations.

For fiscal 2022, the company still projects adjusted earnings in a range of $2.40 to $2.60 per share on adjusted revenues now expected between $15.4 billion and $16.0 billion, down from the prior guidance range of $15.6 billion to $16.2 billion.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $2.51 per share on revenues of $15.97 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT